SCHEMBL3634652

SCHEMBL3634652

CCOc1ccc2c(c1)C(CC(=O)OC)N(c1ccccc1)S2(=O)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 2/20 0.52
APOBEC3A P31941 1/20 0.44
DUSP3 P51452 1/20 0.44
PTPN5 P54829 1/20 0.44
PTPN11 Q06124 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
CACNA1G O43497 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 4/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NOD2 Q9HC29 1/20 0.37
NOD1 Q9Y239 1/20 0.37
ATM Q13315 1/20 0.37
ADAM17 P78536 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
TP53 P04637 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773365 0.90 CTDSP1 (0.62) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3633816 0.90 CTDSP1 (0.57) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3762698 0.88 CTDSP1 (0.46) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3767808 0.85 CTDSP1 (0.56) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3766960 0.84 CTDSP1 (0.53) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3634346 0.84 CTDSP1 (0.55) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3763174 0.84 CTDSP1 (0.50) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3763396 0.84 CTDSP1 (0.52) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3634049 0.84 CTDSP1 (0.52) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3768510 0.84 CTDSP1 (0.54) CTDSP1APOBEC3ADUSP3PTPN5PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
EP-2155703-A1 BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Inhibox Ltd. (GB) 2010-02-24 EP disclosed
WO-2008142376-A1 BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS INHIBOX LTD. (GB) 2008-11-27 WO disclosed
WO-2008142376-A1 BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS INHIBOX LTD. (GB) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents TNF, CS, COASY CTDSP1 725/4885APOBEC3A 3215/4885DUSP3 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.